Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

How Operation Warp Speed Helps Clear Obstacles To COVID-19 Vaccine Production

Executive Summary

Military workers filling in for quality control, manufacturers comparing supply lists, other measures to accelerate the manufacturing pace are noted in US congressional advisory group's report.

You may also be interested in...



Pandemic Perspectives: Paul Offit On COVID-19 Vaccine Worries, Country’s Worst Biological Disaster, And What Lies Ahead

The prominent virologist and vaccine expert talks to the Pink Sheet about how COVID-19 vaccines could change future research, the ‘Rosetta Stone’ of the polio vaccine tragedy, and the 26-year effort to create a rotavirus vaccine.

COVID-19 Vaccine Manufacturers Are Not Enthusiastic About Using Defense Production Act

Pfizer and Moderna execs note they have sufficient resources with their partners to meet their vaccine production commitments. J&J, which has a manufacturing arrangement with Sanofi, is ready to ship four million doses of its vaccine upon receiving authorization from FDA.

Remote Regulatory Assessments Will Continue Post Pandemic, Says US FDA

The US FDA has issued guidance on how it will continue to use remote technology to assess agency regulated facilities, a practice that became popular during COVID-19 travel restrictions.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS143777

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel